Latest Laboratory techniques Stories

SEATTLE, Jan. 29, 2013 /PRNewswire/ -- LifeSpan BioSciences, Inc. (LSBio), the world's leading provider of high quality, immunohistochemistry (IHC) validated research antibodies, announced today that it has added more than 1,200 proprietary IHC-plus(TM) antibodies to its catalog. The additions include a collection of nearly 900 antibodies targeting G Protein-Coupled Receptors (GPCRs), an important family of proteins that are the targets for nearly one-third of all pharmaceutical...

FREMONT, Calif., Jan. 28, 2013 /PRNewswire/ -- WaferGen Bio-systems, Inc. (OTCBB: WGBS) today announced the results of a successful study of lncRNA markers associated with prostate cancer in the lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center. The results can be viewed in white paper form at: http://www.wafergen.com/wp-content/uploads/2013/01/UM_lncRNA_TNf.pdf Under an existing agreement, WaferGen holds a license to this and other lncRNA-based research...

Report would provide an in-depth analysis of the global Isothermal Nucleic Acid Amplification Technologies market including the technology landscape analysis, applications in molecular diagnostics and research laboratories. (PRWEB) January 27, 2013 According to a new market research report, “Isothermal Nucleic Acid Amplification Technologies (INAAT) Market (2012-2017)”, published by MarketsandMarkets, Isothermal nucleic acid amplification technologies emphasizing on its applications...

Dr. Vegh-Goyarts on advancements in anti-cancer therapy Plainview, NY (PRWEB) January 25, 2013 January 2013 – Leukemias and lymphomas are hematological malignancies, originating from the blood cell forming organs, such as the bone marrow and the lymph nodes. More than 100,000 cases of leukemia and lymphoma are diagnosed in the United States every year resulting in more than 50,000 deaths. Survival rates for cancer have improved dramatically over the past decades, and the five-year...

Symbol:  CXG.A-CDNX www.clemex.com Shares Outstanding:  30,999,810 MONTREAL, Jan. 21, 2013 /CNW Telbec/ - Clemex Technologies Inc. (TSXV: CXG.A), designer and manufacturer of Image Analysis systems and software for microscopy applications, is pleased to announce the appointment of Monique Dallaire, currently VP Product Development and Marketing, a new position as Chief Operations Officer of the Company.  Mrs. Dallaire, who holds a Bachelor's degree in engineering from McGill...

[130 Slides Report]Global Transfection Technologies Market (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) And Types (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) (2012 – 2017) (PRWEB) January 20, 2013 The report "Global Transfection Technologies Market - (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) And Types (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA...

AUSTIN, Texas, Jan. 15, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that it has received FDA clearance for its xTAG Gastrointestinal Pathogen Panel (GPP), the first comprehensive molecular diagnostic assay that tests for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single assay. The xTAG GPP assay can be an important clinical tool in the management of gastrointestinal infections, and is now available in...

FREMONT, Calif., Jan. 8, 2013 /PRNewswire/ -- WaferGen Bio-systems, Inc. (OTCBB: WGBS) today announced the successful completion of a proof-of-concept study using its newly-developed proprietary nano-qPCR technology for sample preparation prior to targeted re-sequencing on Next-Gen platforms. The results can be viewed in white paper form at: http://www.wafergen.com/wp-content/uploads/2013/01/TargetEnrchmnt_NGS_WPf.pdf Target enrichment with uniform coverage...

CAMBRIDGE, Mass., Jan. 7, 2013 /PRNewswire/ -- IntelligentMDx (privately held) announced today that it has entered into a multi-year development and license agreement with QIAGEN (NASDAQ: QGEN, Frankfurt Prime Standard: QIA) to design, develop and manufacture several undisclosed CE-marked and FDA cleared diagnostic tests for use on QIAGEN's flagship QIAsymphony RGQ automated platform. Financial terms have not been disclosed. (Logo:...

CAMBRIDGE, Mass., Jan. 7, 2013 /PRNewswire/ -- IMDx (privately held) announced today that it has entered into a multi-year development and license agreement with QIAGEN (NASDAQ: QGEN, Frankfurt Prime Standard: QIA) to design, develop and manufacture several undisclosed CE-marked and FDA cleared diagnostic tests for use on QIAGEN's flagship QIAsymphony RGQ automated platform. Financial terms have not been disclosed. (Logo: http://photos.prnewswire.com/prnh/20120306/NE63745LOGO )...